Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(12):1630–1635. doi: 10.1038/bjc.1997.608

The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma.

A J Staal-van den Brekel 1, A M Schols 1, M A Dentener 1, G P ten Velde 1, W A Buurman 1, E F Wouters 1
PMCID: PMC2228201  PMID: 9413953

Abstract

A disturbed energy balance has been demonstrated in lung cancer patients. Both an enhanced resting energy expenditure (REE) and a decreased energy intake contribute to weight loss. Enhanced systemic levels of inflammatory mediators were found to be related to the enhanced REE in lung cancer. The aim of the present study was to investigate energy metabolism and systemic levels of inflammatory mediators in small-cell lung carcinoma (SCLC) patients before and after treatment with chemotherapy. Hypermetabolism and an enhanced inflammatory response have already been demonstrated in SCLC by our group before. Twelve newly diagnosed SCLC patients were consecutively included in the study. REE was measured by indirect calorimetry and body composition was determined by bioelectrical impedance (BIA) before and 1 month after treatment. To assess the inflammatory state the acute-phase proteins, C-reactive protein (CRP) and lipopolysaccharide-binding protein (LBP), both soluble tumour necrosis factor (TNF) receptors, (sTNF-R)-55 and sTNF-R75, and soluble intercellular adhesion molecule (sICAM)-1 were measured in plasma before and 1 month after treatment. CRP was assessed by turbidemetry, whereas the other inflammatory parameters were measured by enzyme-linked immunosorbent assay (ELISA). A significant reduction in REE was found irrespective of therapeutic outcome, whereas body weight and body composition remained stable. The acute-phase proteins CRP and LBP were reduced significantly after treatment with chemotherapy, whereas both sTNF receptors and sICAM-1 remained enhanced. No correlation, however, existed between the decrease in REE and the decrease in the acute-phase proteins. In conclusion, chemotherapeutic treatment attenuates the tumour-related metabolic derangements and acute-phase response.

Full text

PDF
1630

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Englemann H., Hornik V., Skornick Y., Levo Y., Wallach D., Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991 Oct 15;51(20):5602–5607. [PubMed] [Google Scholar]
  2. Becker J. C., Dummer R., Hartmann A. A., Burg G., Schmidt R. E. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol. 1991 Dec 15;147(12):4398–4401. [PubMed] [Google Scholar]
  3. Black P. H. Shedding from normal and cancer-cell surfaces. N Engl J Med. 1980 Dec 11;303(24):1415–1416. doi: 10.1056/NEJM198012113032411. [DOI] [PubMed] [Google Scholar]
  4. Brockhaus M., Bar-Khayim Y., Gurwicz S., Frensdorff A., Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int. 1992 Sep;42(3):663–667. doi: 10.1038/ki.1992.332. [DOI] [PubMed] [Google Scholar]
  5. Christiansen I., Gidlöf C., Wallgren A. C., Simonsson B., Tötterman T. H. Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood. 1994 Nov 1;84(9):3010–3016. [PubMed] [Google Scholar]
  6. Chumlea W. C., Baumgartner R. N. Status of anthropometry and body composition data in elderly subjects. Am J Clin Nutr. 1989 Nov;50(5 Suppl):1158–1235. doi: 10.1093/ajcn/50.5.1158. [DOI] [PubMed] [Google Scholar]
  7. Collichio F. A., Woolf P. D., Brower M. Management of patients with small cell carcinoma and the syndrome of ectopic corticotropin secretion. Cancer. 1994 Mar 1;73(5):1361–1367. doi: 10.1002/1097-0142(19940301)73:5<1361::aid-cncr2820730509>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Denz H., Orth B., Weiss G., Gallati H., Herrmann R., Huber P., Wachter H., Fuchs D. Serum soluble tumour necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur J Cancer. 1993;29A(16):2232–2235. doi: 10.1016/0959-8049(93)90212-x. [DOI] [PubMed] [Google Scholar]
  9. Deurenberg P., Weststrate J. A., Paymans I., van der Kooy K. Factors affecting bioelectrical impedance measurements in humans. Eur J Clin Nutr. 1988 Dec;42(12):1017–1022. [PubMed] [Google Scholar]
  10. Digel W., Porzsolt F., Schmid M., Herrmann F., Lesslauer W., Brockhaus M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest. 1992 May;89(5):1690–1693. doi: 10.1172/JCI115769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Falconer J. S., Fearon K. C., Plester C. E., Ross J. A., Carter D. C. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994 Apr;219(4):325–331. doi: 10.1097/00000658-199404000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fong Y., Moldawer L. L., Marano M., Wei H., Barber A., Manogue K., Tracey K. J., Kuo G., Fischman D. A., Cerami A. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol. 1989 Mar;256(3 Pt 2):R659–R665. doi: 10.1152/ajpregu.1989.256.3.R659. [DOI] [PubMed] [Google Scholar]
  13. Fredrix E. W., Saris W. H., Soeters P. B., Wouters E. F., Kester A. D., von Meyenfeldt M. F., Westerterp K. R. Estimation of body composition by bioelectrical impedance in cancer patients. Eur J Clin Nutr. 1990 Oct;44(10):749–752. [PubMed] [Google Scholar]
  14. Fredrix E. W., Soeters P. B., von Meyenfeldt M. F., Saris W. H. Measurement of resting energy expenditure in a clinical setting. Clin Nutr. 1990 Dec;9(6):299–304. doi: 10.1016/0261-5614(90)90001-9. [DOI] [PubMed] [Google Scholar]
  15. Fredrix E. W., Wouters E. F., Soeters P. B., van der Aalst A. C., Kester A. D., von Meyenfeldt M. F., Saris W. H. Resting energy expenditure in patients with non-small cell lung cancer. Cancer. 1991 Oct 1;68(7):1616–1621. doi: 10.1002/1097-0142(19911001)68:7<1616::aid-cncr2820680725>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  16. Froon A. H., Bemelmans M. H., Greve J. W., van der Linden C. J., Buurman W. A. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med. 1994 May;22(5):803–809. doi: 10.1097/00003246-199405000-00015. [DOI] [PubMed] [Google Scholar]
  17. Froon A. H., Dentener M. A., Greve J. W., Ramsay G., Buurman W. A. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis. 1995 May;171(5):1250–1257. doi: 10.1093/infdis/171.5.1250. [DOI] [PubMed] [Google Scholar]
  18. Gatanaga M., Grosen E. A., Burger R. A., Granger G. A., Gatanaga T. Release of soluble TNF/LT receptors from a human ovarian tumor cell line (PA-1) by stimulation with cytokines in vitro. Lymphokine Cytokine Res. 1993 Aug;12(4):249–253. [PubMed] [Google Scholar]
  19. Gruss H. J., Dölken G., Brach M. A., Mertelsmann R., Herrmann F. Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. Leukemia. 1993 Aug;7(8):1245–1249. [PubMed] [Google Scholar]
  20. Hansell D. T., Davies J. W., Burns H. J. The effects on resting energy expenditure of different tumor types. Cancer. 1986 Oct 15;58(8):1739–1744. doi: 10.1002/1097-0142(19861015)58:8<1739::aid-cncr2820580826>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  21. Harning R., Mainolfi E., Bystryn J. C., Henn M., Merluzzi V. J., Rothlein R. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res. 1991 Sep 15;51(18):5003–5005. [PubMed] [Google Scholar]
  22. Jebb S. A., Osborne R. J., Dixon A. K., Bleehen N. M., Elia M. Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer. Ann Oncol. 1994 Dec;5(10):915–919. doi: 10.1093/oxfordjournals.annonc.a058730. [DOI] [PubMed] [Google Scholar]
  23. Langkopf F., Atzpodien J. Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet. 1994 Jul 2;344(8914):57–58. [PubMed] [Google Scholar]
  24. Larsen K. Creatinine assay by a reaction-kinetic principle. Clin Chim Acta. 1972 Oct;41:209–217. doi: 10.1016/0009-8981(72)90513-x. [DOI] [PubMed] [Google Scholar]
  25. Leeuwenberg J. F., Jeunhomme T. M., Buurman W. A. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol. 1994 Apr 15;152(8):4036–4043. [PubMed] [Google Scholar]
  26. Leeuwenberg J. F., Smeets E. F., Neefjes J. J., Shaffer M. A., Cinek T., Jeunhomme T. M., Ahern T. J., Buurman W. A. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992 Dec;77(4):543–549. [PMC free article] [PubMed] [Google Scholar]
  27. Lukaski H. C., Johnson P. E., Bolonchuk W. W., Lykken G. I. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985 Apr;41(4):810–817. doi: 10.1093/ajcn/41.4.810. [DOI] [PubMed] [Google Scholar]
  28. McCabe S. M., Riddle L., Nakamura G. R., Prashad H., Mehta A., Berman P. W., Jardieu P. sICAM-1 enhances cytokine production stimulated by alloantigen. Cell Immunol. 1993 Sep;150(2):364–375. doi: 10.1006/cimm.1993.1204. [DOI] [PubMed] [Google Scholar]
  29. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  30. Nelson K. M., Weinsier R. L., Long C. L., Schutz Y. Prediction of resting energy expenditure from fat-free mass and fat mass. Am J Clin Nutr. 1992 Nov;56(5):848–856. doi: 10.1093/ajcn/56.5.848. [DOI] [PubMed] [Google Scholar]
  31. O'Connell J. P., Kris M. G., Gralla R. J., Groshen S., Trust A., Fiore J. J., Kelsen D. P., Heelan R. T., Golbey R. B. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986 Nov;4(11):1604–1614. doi: 10.1200/JCO.1986.4.11.1604. [DOI] [PubMed] [Google Scholar]
  32. Osterlind K., Andersen P. K. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986 Aug;46(8):4189–4194. [PubMed] [Google Scholar]
  33. Ovesen L., Hannibal J., Allingstrup L. Dietary intake in patients with small cell lung cancer: the effect of aggressive chemotherapy. Eur J Clin Nutr. 1992 Jul;46(7):535–537. [PubMed] [Google Scholar]
  34. Patel A. M., Dunn W. F., Trastek V. F. Staging systems of lung cancer. Mayo Clin Proc. 1993 May;68(5):475–482. doi: 10.1016/s0025-6196(12)60197-9. [DOI] [PubMed] [Google Scholar]
  35. Ravussin E., Bogardus C. Relationship of genetics, age, and physical fitness to daily energy expenditure and fuel utilization. Am J Clin Nutr. 1989 May;49(5 Suppl):968–975. doi: 10.1093/ajcn/49.5.968. [DOI] [PubMed] [Google Scholar]
  36. Roh M. S., Ekman L. G., Jeevanandam M., Brennan M. F. Elevated energy expenditure in hepatocytes from tumor-bearing rats. J Surg Res. 1985 May;38(5):407–415. doi: 10.1016/0022-4804(85)90055-1. [DOI] [PubMed] [Google Scholar]
  37. Rothlein R., Czajkowski M., O'Neill M. M., Marlin S. D., Mainolfi E., Merluzzi V. J. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. J Immunol. 1988 Sep 1;141(5):1665–1669. [PubMed] [Google Scholar]
  38. Russell D. M., Shike M., Marliss E. B., Detsky A. S., Shepherd F. A., Feld R., Evans W. K., Jeejeebhoy K. N. Effects of total parenteral nutrition and chemotherapy on the metabolic derangements in small cell lung cancer. Cancer Res. 1984 Apr;44(4):1706–1711. [PubMed] [Google Scholar]
  39. Santarosa M., Favaro D., Quaia M., Spada A., Sacco C., Talamini R., Galligioni E. Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int J Cancer. 1995 Jul 28;62(3):271–275. doi: 10.1002/ijc.2910620307. [DOI] [PubMed] [Google Scholar]
  40. Schols A. M., Dingemans A. M., Soeters P. B., Wouters E. F. Within-day variation of bioelectrical resistance measurements in patients with chronic obstructive pulmonary disease. Clin Nutr. 1990 Oct;9(5):266–271. doi: 10.1016/0261-5614(90)90035-q. [DOI] [PubMed] [Google Scholar]
  41. Shepherd F. A., Laskey J., Evans W. K., Goss P. E., Johansen E., Khamsi F. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):21–27. doi: 10.1200/JCO.1992.10.1.21. [DOI] [PubMed] [Google Scholar]
  42. Shijubo N., Imai K., Aoki S., Hirasawa M., Sugawara H., Koba H., Tsujisaki M., Sugiyama T., Hinoda Y., Yachi A. Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis. Clin Exp Immunol. 1992 Jul;89(1):58–62. doi: 10.1111/j.1365-2249.1992.tb06877.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Shingu M., Hashimoto M., Ezaki I., Nobunaga M. Effect of cytokine-induced soluble ICAM-1 from human synovial cells on synovial cell-lymphocyte adhesion. Clin Exp Immunol. 1994 Oct;98(1):46–51. doi: 10.1111/j.1365-2249.1994.tb06605.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Staal-van den Brekel A. J., Dentener M. A., Schols A. M., Buurman W. A., Wouters E. F. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol. 1995 Oct;13(10):2600–2605. doi: 10.1200/JCO.1995.13.10.2600. [DOI] [PubMed] [Google Scholar]
  45. Staal-van den Brekel A. J., Schols A. M., Dentener M. A., ten Velde G. P., Buurman W. A., Wouters E. F. Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls. Thorax. 1997 Apr;52(4):338–341. doi: 10.1136/thx.52.4.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Staal-van den Brekel A. J., Schols A. M., ten Velde G. P., Buurman W. A., Wouters E. F. Analysis of the energy balance in lung cancer patients. Cancer Res. 1994 Dec 15;54(24):6430–6433. [PubMed] [Google Scholar]
  47. Tsujisaki M., Imai K., Hirata H., Hanzawa Y., Masuya J., Nakano T., Sugiyama T., Matsui M., Hinoda Y., Yachi A. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol. 1991 Jul;85(1):3–8. doi: 10.1111/j.1365-2249.1991.tb05673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wolff J. M., Stephenson R. N., Chisholm G. D., Habib F. K. Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. Eur J Cancer. 1995;31A(3):339–341. doi: 10.1016/0959-8049(94)00446-c. [DOI] [PubMed] [Google Scholar]
  49. Zarowitz B. J., Pilla A. M. Bioelectrical impedance in clinical practice. DICP. 1989 Jul-Aug;23(7-8):548–555. doi: 10.1177/1060028089023007-803. [DOI] [PubMed] [Google Scholar]
  50. von Biberstein S. E., Spiro J. D., Lindquist R., Kreutzer D. L. Enhanced tumor cell expression of tumor necrosis factor receptors in head and neck squamous cell carcinoma. Am J Surg. 1995 Nov;170(5):416–422. doi: 10.1016/s0002-9610(99)80320-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES